DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $628.8 million on a reported basis and 22% on an organic 1 basis.
#cgm
New peer-reviewed research demonstrates that people with diabetes using One Drop sustained clinically and statistically significant reductions in average blood glucose beyond six months and one year, citing meaningful reductions in estimated A1C (eA1C).
Abbott Diabetes Care (NYSE: ABT) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle® Libre system provides significant reductions in glycated hemoglobin (HbA1c) that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.
#cgm
Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system. Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia.
#closed loop
Teladoc (NYSE: TDOC) saw its stock lose about half its value after announcing a $6.6 billion impairment charge amid a challenging integration of Livongo and its health management app. TDOC shares today are trading around $30 apiece, down 50% from where they were before yesterday’s Q1 earnings announcement.
Walmart announced today that its MeMD national telehealth provider partner launched the Walmart Health Virtual Care Diabetes Program. The platform, available as a standalone or as part of a comprehensive medical and behavioral telehealth program, was developed for employers and payors to help their employees and members close gaps in diabetes management.
#telehealth
Participating centers now offer CareSignal’s Deviceless Remote Patient Monitoring® technology to patients to monitor diabetes, hypertension, congestive heart failure, COPD, and social determinants of health.
#product & service
#rpm
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday,May 11, 2022 at 12:00 p.m. Pacific Time.
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children. San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.
#cgm
The aim of this study was to assess the app, specifically its features, handling and impact on diabetes treatment and self-management in Germany.
#mobile app